We are live on ! Find out more
RCP

Rho Capital Partners Portfolio holdings

AUM $20.4M
This Fund
S&P 500
This Quarter Est. Return
-13.61%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$119M
AUM Growth
-$24.7M
Cap. Flow
-$1.58M
Cap. Flow %
-1.32%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
LVO icon
LiveOne
LVO
+$155K

Top Sells

Rank Stock Value
1
TVRD
Tvardi Therapeutics
TVRD
+$1.73M

Sector Composition

Rank Sector Weight
1 Healthcare 93.75%
2 Communication Services 6.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
1
Tvardi Therapeutics
TVRD
$23.5M
$58.4M 48.88%
88,696
-2,083
-2% -$1.73M
NGM
2
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$52.2M 43.68%
3,766,667
– –
LVO icon
3
LiveOne
LVO
$66M
$7.47M 6.25%
372,414
+6,060
+2% +$155K
MRSN
4
DELISTED
Mersana Therapeutics
MRSN
$1.26M 1.05%
31,858
– –
SENS icon
5
Senseonics Holdings Inc
SENS
$254M
$158K 0.13%
7,980
– –

Similar funds

LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

Rho Capital Partners's Q3 2019 Portfolio in Review

As of Q3 2019, Rho Capital Partners held 5 positions worth $119M, down 17% from $144M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2019: portfolio turnover was 0%. Rho Capital Partners opened no new positions and made no exits, leaving the 5-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 89% a quarter earlier, followed by Communication Services.

  • Rho Capital Partners added most to LiveOne in Q3 2019, an estimated $155K increase.
  • Rho Capital Partners's biggest Q3 2019 reduction was Tvardi Therapeutics, cutting an estimated $1.73M.
  • Rho Capital Partners's ten largest holdings make up 100% of its $119M portfolio in Q3 2019.
  • Rho Capital Partners opened 0 new positions and closed 0 in Q3 2019.
  • Rho Capital Partners's portfolio value fell 17% quarter-over-quarter to $119M.

Based on Rho Capital Partners's 13F filing for Q3 2019, filed 12 Nov 2019.